Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
27 shown of 8,320 total abstracts
  1. Abstract LBA4000LBA2026-04-04 · 21:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-411
    H. Borghaei, M. Krop, C. Robert, et al. · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract LBA4001LBA2026-04-01 · 19:15 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    L. Paz-Ares, S. Antonia, E. Winer, et al. · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract LBA4002LBA2026-04-01 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-127
    R. Herbst, F. Andre, J. Brahmer, et al. · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract LBA4003LBA2026-04-04 · 14:00 CT · S406
    PALOMA-202: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    S. Peters, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract LBA4004LBA2026-04-02 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-20 study)
    F. Andre, H. Rugo, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract LBA4005LBA2026-04-03 · 15:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-74 study)
    F. Andre, M. Reck, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract LBA4006LBA2026-04-03 · 13:30 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Modi, C. Robert, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract LBA4007LBA2026-04-01 · 13:30 CT · S100A
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-385
    C. Robert, N. Rizvi, J. Cortes, et al. · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract LBA4008LBA2026-04-03 · 16:45 CT · S406
    MONALEESA-90: Kisqali (ribociclib) maintenance in HR+ breast cancer
    S. Modi, J. Cortes, S. Tolaney, et al. · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract LBA4009LBA2026-04-03 · 18:00 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-86
    J. Cortes, J. Brahmer, N. Rizvi · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract LBA4010LBA2026-04-01 · 14:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-266
    M.C. Garassino, C. Saura · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract LBA4011LBA2026-04-04 · 19:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-622
    C. Robert, H. Borghaei, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract LBA4012LBA2026-04-05 · 18:30 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-761
    S. Modi, C. Saura, S. Peters · Karolinska Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract LBA4013LBA2026-04-04 · 19:00 CT · Arie Crown Theater
    PALOMA-537: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    L. Paz-Ares, M. Reck, S. Antonia, et al. · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract LBA4014LBA2026-04-03 · 13:15 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    T. Mok, E. Winer, S. Modi, et al. · Cleveland Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract LBA4015LBA2026-04-03 · 16:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-138
    N. Rizvi, S. Peters, M. Krop, et al. · Karolinska Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract LBA4016LBA2026-04-04 · 18:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-135 study)
    A. Spira, J. Cortes, C. Robert · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract LBA4017LBA2026-04-05 · 14:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-221 study)
    R. Herbst, E. Winer, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract LBA4018LBA2026-04-01 · 18:30 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    R. Herbst, S. Tolaney, A. Spira, et al. · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract LBA4019LBA2026-04-05 · 13:00 CT · Arie Crown Theater
    MONARCH-886: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M.C. Garassino, F. Andre, H. Rugo · Memorial Sloan Kettering Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract LBA4020LBA2026-04-04 · 21:30 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-635
    M. Reck, H. Rugo · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract LBA4021LBA2026-04-02 · 20:45 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-47 study)
    M. Krop, H. Rugo, A. Spira, et al. · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract LBA4022LBA2026-04-05 · 13:30 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-9
    M.C. Garassino, J. Brahmer, C. Robert · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract LBA4023LBA2026-04-04 · 18:30 CT · S406
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-855
    H. Borghaei, F. Andre, N. Rizvi, et al. · MD Anderson Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract LBA4024LBA2026-04-05 · 20:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-341
    E. Winer, A. Spira, R. Herbst · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract LBA4025LBA2026-04-03 · 13:15 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-422
    M. Reck, L. Paz-Ares, E. Winer · Cleveland Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract LBA4026LBA2026-04-05 · 19:00 CT · S406
    IMpower-241: Tecentriq (atezolizumab) 3L+ in TNBC
    E. Winer, C. Saura, F. Andre, et al. · Institut Gustave Roussy
    Plenary SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.